Open Access
Issue
Published:
28 September 2023
2023 China Guidelines for Lipid Management
Download citation
995
Views
82
Downloads
4
Crossref
1
WoS
1
Scopus
0
CSCD
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of China guidelines for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD. The level of LDL-C, which can be regarded as appropriate in a population without frisk factors, can be considered abnormal in people at high risk of developing ASCVD. As a result, the “Guidelines for the prevention and treatment of dyslipidemia” were adapted into the “China Guidelines for Lipid Management” (henceforth referred to as the new guidelines) by an Experts’ committee after careful deliberation. The new guidelines still recommend LDL-C as the primary target for lipid control, with CVD risk stratification to determine its target value. These guidelines recommend that moderate intensity statin therapy in adjunct with a heart-healthy lifestyle, be used as an initial line of treatment, followed by cholesterol absorption inhibitors or/and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as necessary. The new guidelines provide guidance for lipid management across various age groups, from children to the elderly. The aim of these guidelines is to comprehensively improve the management of lipids and promote the prevention and treatment of ASCVD by guiding clinical practice.
menu
2023 China Guidelines for Lipid Management
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of China guidelines for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD. The level of LDL-C, which can be regarded as appropriate in a population without frisk factors, can be considered abnormal in people at high risk of developing ASCVD. As a result, the “Guidelines for the prevention and treatment of dyslipidemia” were adapted into the “China Guidelines for Lipid Management” (henceforth referred to as the new guidelines) by an Experts’ committee after careful deliberation. The new guidelines still recommend LDL-C as the primary target for lipid control, with CVD risk stratification to determine its target value. These guidelines recommend that moderate intensity statin therapy in adjunct with a heart-healthy lifestyle, be used as an initial line of treatment, followed by cholesterol absorption inhibitors or/and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as necessary. The new guidelines provide guidance for lipid management across various age groups, from children to the elderly. The aim of these guidelines is to comprehensively improve the management of lipids and promote the prevention and treatment of ASCVD by guiding clinical practice.
References(259)
Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol 2019; 16: 203−212.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459−2472.
Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388−2398.
Joint Committee on Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chin J Cardiol 2007; 35: 390−419. (In Chinese).
Chinese Cardiovascular Journal Editorial Board Dyslipidemia Prevention and Treatment Countermeasures Special Group. Recommendations for Prevention and Treatment of Dyslipidemia. Chin J Cardiol 1997; 25: 169−172. (In Chinese).
Joint Committee on Chinese Guideline for the Management of Dyslipidemia in Adults. 2016 Chinese Guideline for the Management of Dyslipidemia in Adults. Chin Circ J 2016; 31: 937−953. (In Chinese).
National Society of Cardiometabolic Medicine. Chinese Expert Recommendations on Lipid Management Options for Community Hospitals (2022 Edition). Chin Circ J 2022; 37: 1181−1185. (In Chinese).
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713−1722.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380: 11−22.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082−e1143.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111−188.
Yang W, Xiao J, Yang Z, et al. Serum lipids and lipoproteins in Chinese men and women. Circulation 2012; 125: 2212−2221.
Ding W, Cheng H, Yan Y, et al. 10-year trends in serum lipid levels and dyslipidemia among children and adolescents from several schools in Beijing, China. J Epidemiol 2016; 26: 637−645.
Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163, 641 adults. Int J Cardiol 2018; 260: 196−203.
Song PK, Man QQ, Li H, et al. Trends in lipids level and dyslipidemia among Chinese adults, 2002-2015. Biomed Environ Sci 2019; 32: 559−570.
NCD Risk Factor Collaboration. Repositioning of the global epicentre of non-optimal cholesterol. Nature 2020; 582: 73−77.
Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circ Cardiovasc Qual Outcomes 2010; 3: 243−252.
Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis 2016; 248: 2−9.
Ding W, Dong H, Mi J. Prevalence of dyslipidemia in Chinese children and adolescents: a Meta-analysis. Chin J Epidemiol 2015; 36: 71−77. (In Chinese).
Wang Z, Zou Z, Yang Y, et al. The epidemiological characteristics and related factors of dyslipidemia among children and adolescents aged 6-17 years from 7 provinces in China, 2012. Chin J Prev Med 2018; 52: 798−801. (In Chinese).
Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology. Chinese Expert Consensus on Lipid Management of Very High-Risk Atherosclerotic Cardiovascular Disease Patients. Chin J Cardiol 2020; 48: 280−286. (In Chinese).
Zeng Y, Liu J, Liu J, et al. The expanding needs on lipid-lowering treatment in patients with acute coronary syndrome by applying newly issued definition of extreme high-risk by chinese society of cardiology. Chin J Cardiol 2020; 48: 1039−1046. (In Chinese).
Li S, Liu HH, Guo YL, et al. Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study. Lancet Reg Health West Pac 2021; 17: 100286.
Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41: 2313−2330.
Ong KL, McClelland RL, Allison MA, et al. Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors. Metabolism 2021; 116: 154706.
Li JJ, Ma CS, Zhao D, et al. Lipoprotein(a) and cardiovascular disease in Chinese population: A Beijing Heart Society Expert Scientific Statement. JACC Asia 2022; 2: 653−665.
Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol 2022; 79: 757−768.
Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345−1361.
Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation 2018; 138: 770−781.
Chait A, Ginsberg HN, Vaisar T, et al. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes 2020; 69: 508−516.
Raposeiras-Roubin S, Rossello X, Oliva B, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021; 77: 3031−3041.
Yan S. Recommendations for Clinical Lipid Profile Testing (in Chinese). Chin J Lab Med 2003; 26: 182−184.
Laboratory Medicine Society of Chinese Medical Association, Branch of Laboratory Physicians of Chinese Medical Doctor Association, Lipids and Lipoproteins Committee, Chinese Society of Biochemistry and Molecular Biology, National Health Commission Clinical Laboratory Center, Editorial Board of Chinese Journal of Laboratory Medicine. China guideline for clinical lipid profile testing. Chin J Lab Med 2022; 45: 1017−1033. (In Chinese).
Yan S. The link between lipid profile testing and clinical practice should be further strengthened. Chin J Clin Lab Sci 2008; 26: 243−245. (In Chinese).
Liu L, Zhao S. Expert consensus on the non-fasting blood lipid detection and clinical application. Chin J Intern Med 2021; 60: 400−405. (In Chinese).
Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol 2015; 9: 129−169.
He Z, Yan S. LDL-C measurement: status and development. Exp & Lab Med 2021; 39: 1327−1332. (In Chinese).
Gotto AM, Jr. , Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease:a working group report and update. J Am Coll Cardiol 2004; 43: 717−724.
Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019; 13: 374−392.
Beijing Society of Cardiology. Expert statement on the relationship between lipoprotein(a) and cardiovascular disease risk and clinical management. Chin Circ J 2021; 36: 1158−1167. (In Chinese).
Wu J, Wang J. Advances in the application and detection of small dense low-density lipoprotein. Chin J Lab Med 2017; 40: 417−420. (In Chinese).
Xu RX, Li S, Li XL, et al. High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. J Clin Lipidol 2015; 9: 26−34.
Zhang J, Peng H, Li G, et al. Clinical value of remnant lipoproteins and low density lipoprotein cholesterol particle concentration detected by vertical auto profile on the diagnosis of carotid plaque. Chin J Lab Med 2022; 45: 575−581. (In Chinese).
Cholesterol treatment trialists collaboration. efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174, 000 participants in 27 randomised trials. Lancet 2015; 385: 1397−1405.
Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566−1579.
Liu J, Hong Y, D'Agostino RB, Sr. , et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291: 2591−2599.
Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 2006; 114: 2217−2225.
Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: The China-PAR Project (Prediction for ASCVD Risk in China). Circulation 2016; 134: 1430−1440.
Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 2016; 134: 1419−1429.
Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol 2017; 69: 911−921.
Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. Circulation 2018; 138: 756−766.
Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association. Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Chin J Cardiol 2020; 48: 1000−1038. (In Chinese).
Zhao S. Lipids Lecture 4: Clinical manifestations and types of hyperlipidemia. Chin J Clinicians 2003; 31: 23−24. (In Chinese).
Expert Dyslipidemia Panel. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 2013; 7: 561−565.
Sun D, Zhou BY, Li S, et al. Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation. Lipids Health Dis 2018; 17: 252.
Cao YX, Sun D, Liu HH, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC Asia 2021; 1: 82−89.
Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478−3490a.
Sharifi M, Rakhit RD, Humphries SE, Nair D. Cardiovascular risk stratification in familial hypercholesterolaemia. Heart 2016; 102: 1003−1008.
Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45: 1274−1283.
Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2: 655−666.
Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316: 1289−1297.
Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302−1309.
Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc 2014; 3: e000759.
Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412−423.
Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 2014; 64: 851−860.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195−2207.
Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670−1681.
Ridker PM, Mora S, Rose L, Group JTS. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 2016; 37: 1373−1379.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387−2397.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097−2107.
Wang Y, Feng L, Zeng G, et al. Effects of cuisine-based chinese heart-healthy diet in lowering blood pressure among adults in China: multicenter, single-blind, randomized, parallel controlled feeding trial. Circulation 2022; 146: 303−315.
Ginsberg HN, Karmally W, Siddiqui M, et al. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscler Thromb 1994; 14: 576−586.
Ginsberg HN, Karmally W, Siddiqui M, et al. Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women. Arterioscler Thromb Vasc Biol 1995; 15: 169−178.
Tanasescu M, Cho E, Manson JE, Hu FB. Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr 2004; 79: 999−1005.
Djousse L, Gaziano JM, Buring JE, Lee IM. Egg consumption and risk of type 2 diabetes in men and women. Diabetes Care 2009; 32: 295−300.
Zhong VW, Van Horn L, Cornelis MC, et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA 2019; 321: 1081−1095.
Zhao SP, Yu BL, Peng DQ, Huo Y. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Atherosclerosis 2014; 233: 707−712.
Collaborative Group on Xuezhikang for Secondary Prevention of Coronary Artery Disease. China Coronary Secondary Prevention Study (CCSPS). Chin J Cardiol 2005; 33: 109−115. (In Chinese).
Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101: 1689−1693.
Li JJ, Lu ZL, Kou WR, et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Ann Med 2010; 42: 231−240.
Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010; 105: 664−666.
Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet 2022; 400: 380−390.
O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 2022; 146: 1109−1119.
Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR Variants with risk of coronary heart disease. JAMA 2019; 321: 364−373.
Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022; 387: 1923−1934.
Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090−1098.
Hu Y, Hu FB, Manson JE. Marine Omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc 2019; 8: e013543.
Wiggins BS, Saseen JJ, Page RL, 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2016; 134: e468−e495.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383−1389.
Willerson JT. Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1996; 94: 3054.
Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349−1357.
Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711−1718.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7−22.
Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215−3222.
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495−1504.
de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307−1316.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425−1435.
Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study:a randomized controlled trial. JAMA 2005; 294: 2437−2445.
Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556−1565.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301−1307.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615−1622.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685−696.
Byrne P, Demasi M, Jones M, et al. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis. JAMA Intern Med 2022; 182: 474−481.
Chen H, Ren J, Wu B, et al. The effects after withdrawal of simvastatin on brachial artery endothelial function in patient with coronary heart disease or risk factors. Chin J Cardiol 2007; 35: 531−535. (In Chinese).
Li JJ, Yang P, Liu J, et al. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clin Chim Acta 2012; 413: 139−142.
Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004; 110: 915−920.
McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task F. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97: 89C−94C.
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012−1022.
Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 2015; 241: 409−418.
Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011; 124: 2233−2242.
McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012; 43: 2149−2156.
Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581−590.
Geng Q, Ren J, Song J, et al. Meta-analysis of the effect of statins on renal function. Am J Cardiol 2014; 114: 562−570.
Li JJ, Liu HH, Wu NQ, et al. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin Drug Metab Toxicol 2020; 16: 837−851.
Ruan Z, Jiang B, Chen J, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects. J Clin Pharmacol 2014; 54: 1144−1152.
Chen J, Lou H, Jiang B, et al. Simultaneous determination of hyzetimibe and its main active metabolite in plasma by LC-MS/MS and its application in PK study. Bioanalysis 2015; 7: 1857−1867.
Liao J, Wang X, Li Z, Ouyang D. Pharmacokinetic study of oral (14)C-radiolabeled hyzetimibe, a new cholesterol absorption inhibitor. Front Pharmacol 2021; 12: 665372.
Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154−156.
Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 2014; 54: 273−293.
Han Y, Ma Y, Su G, et al. Efficacy and safety of alirocumab versus ezetimibe in high cardiovascular risk chinese patients with hyperlipidemia: ODYSSEY EAST Study-Chinese Sub-Population Analysis. Chin J Cardiol 2022; 48: 593−599. (In Chinese).
Chen Y, Yuan Z, Lu J, et al. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab 2019; 21: 1464−1473.
Thedrez A, Blom DJ, Ramin-Mangata S, et al. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab. Arterioscler Thromb Vasc Biol 2018; 38: 592−598.
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489−1499.
Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014; 114: 711−715.
Cao YX, Liu HH, Li S, Li JJ. A Meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am J Cardiovasc Drugs 2019; 19: 87−97.
Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500−1509.
Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opin Drug Saf 2014; 13: 1023−1030.
Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med 2017; 377: 633−643.
Fitzgerald K, White S, Borodovsky A, et al. A Highly Durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 2017; 376: 41−51.
Yamashita S, Bujo H, Arai H, et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008; 15: 292−303.
Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110: 352−360.
Xu D, Shu J, Huang Q, et al. Comparative Study of the Efficacy and Safety of Zhibitai and Atorvastatin. Chin J Intern Med 2010; 49: 392−395. (In Chinese).
Xu DY, Shu J, Huang QY, et al. Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. Atherosclerosis 2010; 211: 237−241.
Hu D. Expert Consensus on the Clinical Application of Polyhexanol: A New Lipid-Regulating Phytopharmaceutical. Chin J Intern Med 2008; 47: 961−963. (In Chinese).
Liu S, Tan M, Zhao S, Rong H. Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia. Chin J Cardiol 2012; 40: 840−843. (In Chinese).
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410−418.
Chu J, Ye P, Kou W, et al. Efficacy and tolerability study of micronized fenofibrate in the treatment of dyslipidemia. Chin J Cardiol 2002; 30: 27−30. (In Chinese).
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849−1861.
Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563−1574.
Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875−1884.
Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 2017; 16: 124.
Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988; 318: 549−557.
Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation 2019; 140(12): e673−e691.
Kelley DS, Adkins Y. Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Proc Nutr Soc 2012; 71: 322−331.
Harris WS. n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 1996; 31: 243−252.
Khan SU, Lone AN, Khan MS, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine 2021; 38: 100997.
Nishizaki Y, Miyauchi K, Iwata H, et al. Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. Am Heart J 2022; 257: 1−8.
Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013; 61: 440−446.
Hps Thrive Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203−212.
Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998−1006.
Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381: 40−46.
Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA 2019; 322: 1780−1788.
Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380: 1022−1032.
Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 2020; 383: 711−720.
Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 2019; 381: 531−542.
Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 2022; 327: 1679−1687.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in persons with cardiovascular disease. N Engl J Med 2020; 382: 244−255.
Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21, 000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251−261.
Masana L, Pedro-Botet J, Civeira F. IMPROVE-IT clinical implications. Should the “high-intensity cholesterol-lowering therapy” strategy replace the “high-intensity statin therapy”? Atherosclerosis 2015; 240: 161−162.
LT Q, SP Z, JY C, et al. Efficacy and safety of hybutimibe on primary hypercholesterolemia: a randomized, double-blinded, placebo and positive-controlled, parallel phase II study. Cardiol Plus 2022; 7: 77−84.
Qi L, Chen J, Li X, et al. Efficacy and safety of hybutimibe in combination with atorvastatin for treatment of hypercholesteremia among patients with atherosclerotic cardiovascular disease risk equivalent: A multicenter, randomized, double-blinded phase III study. Front Cardiovasc Med 2022; 9: 888604.
Zhao Y, Peng R, Zhao W, et al. Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease. Medicine (Baltimore) 2017; 96: e6104.
Xu D, Hu J, Wu Q, et al. Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease. Oncotarget 2018; 9: 9489−9497.
Li M, Li Y, Chen M, et al. Meta-analysis of Zhibitai Capsules combined with statin in reducing blood lipid levels in patients with coronary heart disease. Chin J Chin Materia Medica 2020; 45: 2966−2974. (In Chinese).
Elam MB, Ginsberg HN, Lovato LC, et al. Association of Fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370−380.
Ren J, Chen H, Luo Y. Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia. Chin J Cardiol 2005; 33: 122−126. (In Chinese).
Zhao S, Wang F, Dai Y, et al. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Int J Cardiol 2016; 221: 832−836.
Roth EM, Bays HE, Forker AD, et al. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. J Cardiovasc Pharmacol 2009; 54: 196−203.
Shearer GC, Pottala JV, Hansen SN, et al. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res 2012; 53: 2429−2435.
Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146−2157.
Zhao L, Gao Y, Liu G, et al. Lipoprotein apheresis in patients with familial hypercholesterolemia: a single center research. Chin J Cardiol 2022; 50: 585−590. (In Chinese).
Heigl F, Hettich R, Lotz N, et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36, 000 treatments at one center in Germany. Atheroscler Suppl 2015; 18: 154−162.
Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019; 291: 62−70.
Harada-Shiba M, Arai H, Ishigaki Y, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb 2018; 25: 751−770.
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149−1158.
Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2021−2031.
Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016; 374: 2032−2043.
ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group and The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998−3007.
Hypertensive Group of Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Expert Consensus on the Comprehensive Management of Blood Pressure and Dyslipidemia in Chinese Hypertensive Patients. Chin J Cardiol 2021; 49: 554−562. (In Chinese).
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181−2192.
Cholesterol Treatment Trialists Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4: 829−839.
Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238−248.
Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395−1407.
Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549−559.
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453−463.
Bohula EA, Wiviott SD, Giugliano RP, et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2017; 136: 2440−2450.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623−1630.
Cholesterol Treatment Trialists Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393: 407−415.
Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2019; 4: 846−854.
Sever P, Gouni-Berthold I, Keech A, et al. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol 2021; 28: 805−812.
Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or Older (EWTOPIA 75): a randomized, controlled trial. Circulation 2019; 140: 992−1003.
Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in caring for pregnant patients: A Scientific Statement From the American Heart Association. Circulation 2020; 141: e884−e903.
Dobert M, Varouxaki AN, Mu AC, et al. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation 2021; 144: 670−679.
Yang Y, Li J, Sun Y. Views on FDA’s withdrawal of strongest warning against using cholesterol-lowering statins during pregnancy. Chin J Cardiol 2022; 50: 851−852. (In Chinese).
Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis 2021; 336: 1−11.
Vahedian-Azimi A, Makvandi S, Banach M, et al. Fetal toxicity associated with statins: A systematic review and meta-analysis. Atherosclerosis 2021; 327: 59−67.
Elkins C, Fruh S, Jones L, Bydalek K. Clinical practice recommendations for pediatric dyslipidemia. J Pediatr Health Care 2019; 33: 494−504.
The Editorial Board of Chinese Journal of Pediatrics, The Subspecialty Group of Child Health Care TSoP, Chinese Medical Association, The Subspecialty Group of Cardiovascular Disease TSoP, Chinese Medical Association, The Subspecialty Group of Atherosclerosis TSoCD, Chinese Medical Association. Experts consensus for prevention and treatment of dyslipidemia in children and adolescents. Chin J Pediatr 2009; 47: 426−428. (In Chinese).
The Subspecialty Group of Rare Diseases TSoP, Chinese Medical Association, The Subspecialty Group of Cardiology TSoP, Chinese Medical Association, The Subspecialty Group of Child Health Care TSoP, Chinese Medical Association, The Subspecialty Group of Endocrinological HaMD, The Society of Pediatrics, Chinese Medical Association, The Editorial Board CJoP. Expert Consensus on Diagnosis and Management of Dyslipidemia in Children. Chin J Pediatr 2022; 20: 633−639. (In Chinese).
Atherosclerosis and Coronary Heart Disease Group of the Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese Expert Consensus on Screening, Diagnosis and Treatment of Familial Hypercholesterolemia. Chin J Cardiol 2018; 46: 99−103. (In Chinese).
Cao YX, Sun D, Liu HH, et al. A Novel Modified System of Simplified Chinese Criteria for Familial Hypercholesterolemia (SCCFH). Mol Diagn Ther 2019; 23: 547−553.
Cao YX, Wu NQ, Sun D, et al. Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease. J Transl Med 2018; 16: 345.
Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2016; 133: 849−858.
Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol 2016; 67: 139−147.
Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459−467.
Xie W, Liang L, Zhao L, et al. Combination of carotid intima-media thickness and plaque for better predicting risk of ischaemic cardiovascular events. Heart 2011; 97: 1326−1331.
Echocardiography Group of Chinese Society of Ultrasound in Medicine. Echocardiography Measurement Guidelines for Chinese Adults. Chin J Ultrasonogr 2016; 25: 645−666. (In Chinese).
Zhang H, Hu L, Wei X. Prognostic value of left ventricular hypertrophy in hypertensive patients: A meta-analysis of electrocardiographic studies. J Clin Hypertens (Greenwich) 2020; 22: 254−260.
Sheng Y, Li M, Xu M, et al. Left ventricular and atrial remodelling in hypertensive patients using thresholds from international guidelines and EMINCA data. Eur Heart J Cardiovasc Imaging 2022; 23: 166−174.
Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337−345.
Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307: 2499−2506.
Cao Y, Yan L, Guo N, et al. Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2019; 147: 1−8.
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626−635.
Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res 2016; 118: 547−563.
Madsen CM, Varbo A, Nordestgaard BG. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J 2018; 39: 610−619.
Beaumont JL, Carlson LA, Cooper GR, et al. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ 1970; 43: 891−915.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001−1009.
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005−2016.
Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368(9542): 1155−1163.
Diaz R, Li QH, Bhatt DL, et al. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol 2021; 28: 33−43.
Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015; 9: 758−769.
Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA 2016; 315: 1580−1590.
Schreml J, Gouni-Berthold I. Role of Anti-PCSK9 Antibodies in the treatment of patients with statin intolerance. Curr Med Chem 2018; 25: 1538−1548.
Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr 2009; 63(Suppl 2): S5−S21.
Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010; 7: e1000252.
Clifton PM, Keogh JB. A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease. Nutr Metab Cardiovasc Dis 2017; 27: 1060−1080.
Christian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol 2012; 6: 450−461.
Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117−125.
Lee S, Akioyamen LE, Aljenedil S, et al. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. Eur J Prev Cardiol 2019; 26: 1262−1270.
Di Taranto MD, Giacobbe C, Palma D, et al. Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement. Clin Genet 2021; 100: 529−541.
Watts GF, Sullivan DR, Hare DL, et al. Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. Heart Lung Circ 2021; 30: 324−349.
Harada-Shiba M, Ohta T, Ohtake A, et al. Guidance for Pediatric Familial Hypercholesterolemia 2017. J Atheroscler Thromb 2018; 25: 539−553.
Ramaswami U, Humphries SE, Priestley-Barnham L, et al. Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care. Atherosclerosis 2019; 290: 1−8.
Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2019; 2019: CD006401.
Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019; 381: 1547−1556.
Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis 2018; 277: 483−492.
Ishigaki Y, Kawagishi N, Hasegawa Y, et al. Liver transplantation for homozygous familial hypercholesterolemia. J Atheroscler Thromb 2019; 26: 121−127.
Zhao L, Wen J, Guo Y. Research progress of liver transplantation for patients with homozygous familial hypercholesterolemia. Chin J Arterioscler 2021; 29: 353−358. (In Chinese).
FEEDBACK 
TOP